We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As the race for COVID-19 vaccines intensifies, the unprecedented problems of distributing them once they get regulatory approval are coming into focus — including the need for refrigeration throughout the supply chain. Read More
Pfizer and BioNTech are nearing the finish line for a COVID-19 vaccine supply agreement with the European Commission (EC), wrapping up exploratory talks Wednesday and beginning the contract negotiation process for 200 million doses of their candidate. Read More
Sanofi’s chief in France, Olivier Bogillot, announced Tuesday that shots of the company’s COVID-19 vaccine candidate would likely cost below $11.80 (10 Euro) in Europe should it be approved, in the mid-range of prices that drugmakers are disclosing. Read More
Generics company Mylan along with Biocon Biologics launched their diabetes drug Semglee, a version of Lantus, this week, touting it as 65 percent less expensive than other long-acting insulin products on the market. Read More
Nestlé has announced that it will acquire Aimmune Therapeutics for $2.6 billion in a deal that will add Palforzia — the first FDA-approved treatment for patients with peanut allergy — to Nestlé’s pharmaceuticals portfolio. Read More
The Massachusetts-based drugmaker is also in discussions with the European Commission to supply 80 million doses of the vaccine to the European Union. Read More